NASDAQ : MENS
Jyong Biotech Ltd. — Company profile
Healthcare · Biotechnology · Taiwan
Last price 1.88 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 139.56M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Details
| Name | Jyong Biotech Ltd. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 27 |
| Founded | 2002 |
| Ipo Date | 2025-06-17 |
| Ceo | Fu-Feng Kuo |
| Country | Taiwan |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | KYG831161065 |
| Cusip | G83116106 |
| Cik | 1954488 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Fu-Feng Kuo | Chief Executive Officer and Chairwoman of the Board |
| Wei Zhang | Chief Financial Officer |
| Dr. Fenglin Hsu Ph.D. | Chief Technology Officer and Director |
Contact
| Address | No. 95, Xintai 5th Road, 23F-3, New Taipei City, 221, Taiwan |
| Phone | 886 2 2732 5205 |
| Website | https://jyongbio.com |